(SeaPRwire) – SHANGHAI, April 15, 2026 — EpimAb Biotherapeutics, a clinical-stage biotechnology company focused on developing bispecific antibodies and T-cell engagers, is delighted to announce that it will present a poster on its Novel Prodrug T-Cell Engager (ProTCE) Platform at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting. The event will take place at the San Diego Convention Center in San Diego, California, from April 17 to 22, 2026.
The poster will highlight: the ProTCE Platform and initial preclinical proof of concept for EM33. Below are the presentation details:
ProTCE Platform and Its Candidate ProTCE EM33
- Title: A novel, versatile Prodrug T-cell engager platform featuring a candidate that exhibits potent and tumor-specific activity
- Presentation Number: 1610
- Presentation Date: Monday, April 20, 2026
- Presentation Time: 9:00 AM – 12:00 PM, local time (Location: Poster Section 10)
“We are excited to showcase our Prodrug T-cell engager technology platform at the AACR Annual Meeting. This achievement validates the global competitiveness and clinical translation potential of our proprietary innovations, marking a key milestone in advancing the company’s R&D capabilities,” said Dr. Chengbin Wu, Founder and CEO of EpimAb. “Going forward, the platform aims to address critical unmet medical needs and drive the development of safer, more effective therapeutic options for patients worldwide.”
About EpimAb Biotherapeutics, Inc
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical firm specializing in multi-specific antibody development. Leveraging an extensive suite of in-house research and technology capabilities—including its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms—EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets designed to benefit cancer patients. For more information, please visit: www.epimab.com
Investor Contact
Dr. David Gu
Phone: +86-21-61951011
Email: IR@epimab.com
BD Contact
Dr. Jason Tang
Phone: +86-21-61951014
Email: partnering@epimab.com
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.